Sanofi’s AlphaMedix Hits Key Efficacy Goals in Phase 2 Neuroendocrine Tumor Trial 9 October 2025·625 words·3 mins Sanofi AlphaMedix Radioligand Therapy Neuroendocrine Tumors Oncology Biotech Clinical Trials
